IM Cannabis Corp.

IMCC

CA44969Q3070

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 01:11:08 2024-04-26 pm EDT			5-day change	1st Jan Change
0.78 ^CAD	0.00%		-7.14%	+69.57%

Apr. 09	IM Cannabis Corp. and Vessel Brand, Inc. Partner to Bring Vessel Cannabis Accessories to the Israeli Market	CI
Apr. 04	IM Cannabis, Avant Brands Sign BLK MKT's Licensing Deal for German Medical Cannabis Market	MT

IM Cannabis Corp. Reports Earnings Results for the Full Year Ended December 31, 2023

March 28, 2024 at 08:52 am EDT

IM Cannabis Corp. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CAD 48.8 million compared to CAD 54.34 million a year ago.

Net loss was CAD 9.5 million compared to CAD 188.89 million a year ago. Basic loss per share from continuing operations was CAD 0.74 compared to CAD 3.13 a year ago. Diluted loss per share from continuing operations was CAD 0.74 compared to CAD 3.81 a year ago.

Basic loss per share was CAD 0.74 compared to CAD 26.3 a year ago. Diluted loss per share was CAD 0.74 compared to CAD 26.98 a year ago.

Latest news about IM Cannabis Corp.

IM Cannabis Corp. and Vessel Brand, Inc. Partner to Bring Vessel Cannabis Accessories to the Israeli Market	Apr. 09	CI
IM Cannabis, Avant Brands Sign BLK MKT's Licensing Deal for German Medical Cannabis Market	Apr. 04	MT
Transcript : IM Cannabis Corp., 2023 Earnings Call, Mar 28, 2024	Mar. 28
IM Cannabis Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
IM Cannabis Corp. Brief: Notes This Provides IMC Germany with a "Unique Opportunity" to further accelerate growth in 2024 after delivering 180% growth in 2023	Mar. 25	MT
IM Cannabis Corp. Brief: Adds By rescheduling medical cannabis, from a narcotic to a regular prescription, the German medical cannabis market is Expected to deliver "Strong" growth	Mar. 25	MT
IM Cannabis Corp. Brief: Says Expects "Accelerated Growth" in Germany from that Country's "Groundbreaking" Cannabis Legalization	Mar. 25	MT
IM Cannabis Corp. Announces German Government's Final Approval of Legalizing Cannabis	Mar. 25	CI
IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company	Feb. 28	MT
Kadimastem Ltd entered into a non-binding term sheet to acquire IM Cannabis Corp. in reverse merger transaction.	Feb. 27	CI
Avant Brands Brief: Restructuring Loan Agreements to Extend Term and Decrease Payments	Feb. 26	MT
IM Cannabis Brief: Says Received 180 Calendar Day Extension from Nasdaq Stock Market to Regain Compliance with Bid Price Rule	Jan. 31	MT
IM Cannabis Rescheduling Final Payment of the Oranim Pharmacy Acquisition	Jan. 12	MT
IM Cannabis Announced Conclusion of Planning and Construction Legal Proceedings Against Focus Medical	Jan. 02	MT
IM Cannabis Notes New Israeli Cannabis Regulation Delayed by Three Months	Dec. 08	MT
IM Cannabis Announces Receipt of Court Action	Nov. 27	MT
Transcript : IM Cannabis Corp., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
IM Cannabis Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
IM Cannabis Secures $1.39 Million in Short-Term Debt	23-10-13	MT
IM Cannabis Corp. Announces Executive Changes	23-10-10	CI
IM Cannabis CFO Steps Down	23-09-19	MT
IM Cannabis Corp. Announces Departure of Itay Vago as CFO	23-09-19	CI
Transcript : IM Cannabis Corp., Q2 2023 Earnings Call, Aug 14, 2023	23-08-14
IM Cannabis Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
IM Cannabis Brief: Says Received NASDAQ Notification Regarding Minimum Bid Price Deficiency	23-08-04	MT

Chart IM Cannabis Corp.

Duration

Period

More charts

Company Profile

IM Cannabis Corp. is a Canada-based medical cannabis company. The Company operates in Israel through its commercial relationship with Focus Medical Herbs Ltd. (Focus Medical), which has a cultivation license to breed, grow and supply medical cannabis products in Israel. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centres and logistical hubs in Israel. The Company operates through Adjupharm GmbH in Europe, which is a medical cannabis producer and distributor with wholesale, narcotics handling, manufacturing, procurement, storage, and distribution licenses granted by German regulatory authorities that allow for import/export capability with requisite permits. The Company operates through Trichome and its subsidiaries Trichome JWC Acquisition Corp. and MYM Nutraceuticals Inc., where it cultivates and processes cannabis for the adult-use market at its Ontario and Nova Scotia facilities under the WAGNERS and Highland Grow brands.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company